Cargando…
An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect)
OBJECTIVES: In recent years, CapeOX therapy for patients with colorectal cancer is widely used. We previously reported that a multidisciplinary approach decreases the worsening of adverse events and increases patient satisfaction. In this study, we conducted a multicenter, prospective, observational...
Autores principales: | Matsuoka, Hiroshi, Ogata, Yutaka, Nakamura, Michio, Shibata, Yoshihisa, Munemoto, Yoshinori, Bando, Hiroyuki, Nishijima, Koji, Okuda, Hiroyuki, Terada, Itsuro, Shiroiwa, Takeru, Kishimoto, Junji, Maeda, Kotaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Society of Coloproctology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186009/ https://www.ncbi.nlm.nih.gov/pubmed/32346646 http://dx.doi.org/10.23922/jarc.2019-020 |
Ejemplares similares
-
Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX
por: Sasaki, Kenta, et al.
Publicado: (2019) -
Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis
por: Hirata, Fumihiro, et al.
Publicado: (2018) -
Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
por: Fei, Zuo, et al.
Publicado: (2019) -
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016) -
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
por: Nakayama, Goro, et al.
Publicado: (2017)